Pasithea Therapeutics Corp. (KTTA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
KTTA Chart
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Pasithea Therapeutics (KTTA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Pasithea Therapeutics (KTTA) Expected to Announce Quarterly Earnings on Monday
Pasithea Therapeutics (NASDAQ: KTTA - Get Free Report) is projected to announce its results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Pasithea Therapeutics Trading Down 0.9% Shares of KTTA stock opened at $0.82 on Monday. The stock has a market cap
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Pasithea Therapeutics Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Yuen Man Lee Persistent Asset Partners Ltd. | 290,555 | $374,816.01 | $131,824.8 | -$242,991.21 | -64.83% |
Pasithea Therapeutics Corp. (KTTA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pasithea Therapeutics Corp. ever had a stock split?
Pasithea Therapeutics Corp. Profile
| Biotechnology Industry | Healthcare Sector | Tiago Reis Marques CEO | NASDAQ (CM) Exchange | 70261F202 CUSIP |
| US Country | 5 Employees | - Last Dividend | 2 Jan 2024 Last Split | 15 Sep 2021 IPO Date |
Overview
Pasithea Therapeutics Corp. is a pioneering biotechnology firm focused on the research and development of novel treatments for Central Nervous System (CNS) disorders, RASopathies, and various other diseases. With its inception in 2020 and headquarters established in Miami Beach, Florida, the company operates through two distinct segments: Therapeutics and Clinics. In its Clinics segment, Pasithea provides essential business support services to anti-depression clinics, healthcare entities, and registered healthcare providers, aiming to foster advancements in mental health treatments. Through its Therapeutics segment, the company is committed to the discovery and development of groundbreaking therapeutic options, addressing a wide range of medical needs with a particular emphasis on CNS disorders and genetic diseases known as RASopathies.
Products and Services
- PAS-004:
- PAS-003:
- PAS-002:
- PAS-001:
PAS-004 stands as Pasithea Therapeutics Corp.'s leading product candidate, embodying a novel approach in the realm of treatment for RASopathies and selected oncology indications. This next-generation mitogen-activated protein kinase (MEK) inhibitor distinguishes itself through its macrocyclic design, targeting a spectrum of conditions such as neurofibromatosis type 1, Noonan syndrome, lamin A/C cardiomyopathy among others. By focusing on this innovative macrocyclic format, PAS-004 is poised to offer enhanced therapeutic potential and specificity compared to existing treatments.
Targeting the debilitating condition of amyotrophic lateral sclerosis (ALS), PAS-003 represents Pasithea's commitment to combating severe neurodegenerative diseases. By advancing research and development efforts for PAS-003, the company aims to provide a new hope and therapeutic avenue for individuals affected by ALS, a disease that presently has limited treatment options and no cure.
With the development of PAS-002, Pasithea Therapeutics Corp. seeks to address the complex challenges of multiple sclerosis (MS), a chronic autoimmune condition that affects the CNS. This product candidate embodies the firm's dedication to pioneering treatments that can potentially modify the disease course, reduce relapses, and alleviate symptoms for MS patients, emphasizing improved quality of life and disease management.
Pasithea's endeavor to tackle psychiatric disorders is encapsulated in PAS-001, a novel therapeutic candidate aimed at the treatment of schizophrenia. By focusing on this specific mental health condition, the company aspires to contribute significantly to the field, offering new therapeutic options that aim to better manage and treat the complex symptoms associated with schizophrenia.
